



Point of care and dried blood spot HCV testing - a practical introductory workshop

8th September, 2017
Hyatt regency on the Hudson,
Jersey City / New York,
United States.

Co-chairs

Dr Tanya Applegate

The Kirby Institute,

UNSW Sydney Australia



Dr Erika Castro Bataenjer

Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland



Scope of today's workshop

- Increase awareness of point of care testing and sample collection
 - Discuss principles, advantages, limitations
 - Understand what tests are here, what tests are coming
 - Share our experiences, lessons learned
 - Practical demonstrations
 - Open access guidance documents coming soon.....
-

Today's workshop

1. Introduction to POC testing

Tanya Applegate

The Kirby Institute, UNSW Sydney, Australia

2. Antibody testing using rapid diagnostic tests

Jessie Schwartz

NYC Health Department, NY, USA

3. HCV RNA testing using GeneXpert

Francois Lamoury

The Kirby Institute, UNSW Sydney, Australia

4. Dried Blood Spots

Tanya Applegate

Erika Castro


*Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland*

5. Concluding remarks

Erika Castro

- Followed by Orasure demonstration for those interested

The HCV cascade of care



Living with HCV Infection

HCV Antibody Diagnosed

HCV RNA Diagnosed

Linked to HCV Care


Liver Disease Assessed

Initiated HCV Treatment


Cure (SVR)



The HCV cascade of care



WHO 2030 HCV elimination goals



Living with HCV Infection

HCV Antibody Diagnosed

HCV RNA Diagnosed



Linked to HCV Care

Liver Disease Assessed



Initiated HCV Treatment

Cure (SVR)

Target: 90% diagnosed



Target: 80% treated



Increased access to diagnostics – our next challenge



← Prevention →




Increased access to diagnostics – how?




Collaborative partnerships – everyone has a role

1. A quick introduction – point of care testing


How is testing for HCV done now?




Centralized testing




How is testing for HCV done now?



Centralized testing



How can this be improved?




Centralized testing



Take the test to the patient




Decentralized services



Point of care testing

What are “point of care tests” (POCT) ?

A test performed near the patient that changes patient care



Benefits?

- Rapid, simple collection method (finger-prick, oral)
- Enables screening or diagnosis
- Facilitates single visit diagnosis and treatment
- Integration into a range of services
- Improves access for people using these services

The World Health Organization

ASSURED guidelines for POCTs¹

1. Affordable (for populations at risk)
2. Sensitive
3. Specific
4. User-friendly (simple to perform in a few steps with minimal training)
5. Rapid & Robust (results available in less than 30 minutes)
6. Equipment-free
7. Deliverable to those who need them

¹ Peeling RW, et al. Rapid test for sexually transmitted infections (STIs): the way forward. *Sex Transm Infect.* 2006.

Remind me again...what is “sensitivity and specificity”?


Sensitivity = true positive result +++++

Ability to correctly identify those with the disease

Specificity = true negative result +++++

Ability to correctly identify those without the disease

What tools might make it easier to get tested?



Jessie Schwartz

What tools might make it easier to get tested?

Visit #1



Rapid anti-HCV antibody test
(Health care worker)



#2




Phlebotomy
(Phlebotomist)

Central Lab
Antibody test
1-2 weeks

#3



Receive diagnosis
(Physician)



Dried blood spot sample
(Health care worker)

Central Lab
Ab / reflex
RNA test
1-2 weeks



Receive diagnosis
(Physician)

Tanya and Erika

What tools might make it easier to get tested?

Visit #1



Rapid anti-HCV antibody test
(Health care worker)



#2



Phlebotomy
(Phlebotomist)

Central Lab
Antibody test
1-2 weeks

#3



Receive diagnosis
(Physician)



Dried blood spot sample
(Health care worker)

Central Lab
Ab / reflex
RNA test
1-2 weeks



Receive diagnosis
(Physician)



POC HCV RNA and diagnosis
(Health care worker)

Francois Lamoury

Accessing quality tests – approvals and registration



- **Sample type** (eg. plasma, serum, whole blood, capillary, saliva, DBS)
 - **Intended use** (screening, diagnosis, monitoring)
- ⇒ **In country procurement, price negotiations and access**

2. Antibody Testing Using Rapid Hepatitis C Diagnostic Tests in NYC: Tips for Local Implementation

Jessie Schwartz, RN, MPH

*Clinical Coordinator, Viral Hepatitis Program
New York City Health Department*

HCV antibody testing using “Rapid Diagnostic Tests”

- Test kit detect antibodies to HCV (anti-HCV) produced by the body’s immune system – the majority of persons will develop antibodies within 8 weeks of exposure
- Kits can use blood or oral (not in the U.S.) specimens for diagnosis
- Hepatitis C viral testing to confirm infection is crucial; in NYC as many as 50% with a positive anti-HCV test do not have active infection
 - Natural clearance of virus (15-25%)
 - Successful treatment
 - False positives

Many Rapid anti-HCV antibody Diagnostic Tests

Test name	Manufacturer	Country	Certification
SD Bioline HCV	Standard Diagnostics, Inc	South Korea	WHO; CE
OraQuick HCV Rapid Antibody Test	OraSure Technologies, Inc	USA	WHO, FDA; CE
HCV Card	Axiom Diagnostics	Germany	CE
ImmunoFlow HCV	Core Diagnostics	UK	CE
Hepa-Scan HCV card test	Bhat Biotech	India	CE
Toyo anti-HCV test	Türklab A.S.	Turkey	CE
Signal HCV	SPAN Diagnostics Ltd	India	CE
HCVTOP	BioSynex S.A.	France	CE
OneStep HCV Rapid Test	Span Biotech Ltd	China	CE
HCV Rapid Test	UAB Euro Genomas	Lithuania	CE
Hepatitis C Antibody Test	Artron Laboratories	Canada	CE
Diaquick HCV Cassette	Dialab GmbH	Austria	CE
MultiSure HCV	MP Biomedicals,	Singapore	
First Response HCV Card Test	Premier Medical Corporation Ltd	India	
— VEDA.LAB HCV	VEDA.LAB, Alençon	France	Note – list is incomplete!

Two Rapid Diagnostic Tests are WHO prequalified

OraQuick HCV Rapid Antibody Test (OraSure Technologies, Inc)

- **WHO sample type:** oral fluid, fingerstick whole blood, venipuncture whole blood, plasma specimens (EDTA, sodium heparin, lithium heparin, and sodium citrate), and serum (serum separator tube (SST)).
- **CE-marked:** as above.
- **FDA-approved:** All samples except oral in US

SD Bioline (Standard Diagnostics, Inc)

- **WHO sample type:** human serum, plasma (heparin, EDTA and sodium citrate) or venous whole blood. (not fingerstick)
- **CE-marked and FDA-approved** – all samples (not fingerstick)

How to use a Rapid anti-HCV antibody Diagnostic Test



Collect blood
or...



...oral sample



Insert device
into or add
buffer solution



Read results
in 20-40
minutes



Hepatitis C in New York City

- Largest city in the United States
- Estimated that around 146,500 are living with chronic hepatitis C infection³
- Up to 50% not aware of their status⁴
- Highest rates in very high poverty neighborhoods⁵
- Prevalence 71% in persons who inject drugs⁶
- 1.2% increase in rates of newly reported HCV infection in adults aged 20-29 between 2005 - 2015⁵


³ Balter S, et al. *Estimating the prevalence of hepatitis C infection in New York City using surveillance data.* *Epidmiol Infect*, 2014.

⁴ Holemborg SD, et al. *Hepatitis C in the United States.* *NEJM*, 2013.


⁵ New York City Department of Health and Mental Hygiene. *Hepatitis B and C Annual Report, 2015.* Published October, 2016.

⁶ Des Jarlais DC, et al. *Can intranasal drug use reduce HCV infection among injection drug users?* *Drug Alcohol Depend*, 2011.


New York City Hepatitis C Care Cascade (2013)



New York City Hepatitis C Care Cascade (2013)



New York City Hepatitis C Care Cascade (2013)



NYC Hep C Peer Navigation at Syringe Exchange Programs

- Part time peer navigators support people at risk or living with Hep C to complete Hep C testing, link or return to medical care, and prevent infection or re-infection
 - Implemented at 15 NYC syringe exchange and harm reduction programs affiliated with Injection Drug User Health Alliance (IDUHA)
-

Demographics

Gender:

65% male

26% female

7% transgender

Race & ethnicity:

40% Latinx

33% Non-Hispanic Black

Age:

51% 30 – 50 years old

32% 51 – 71 years old

16% 29 years or younger

Psychosocial factors*:

74% mental health issue


65% homeless or unstably housed

61% have injected drugs

42% not aware of Hep C status at intake

NYC Hep C Peer Navigation Program

Implemented at 15 NYC syringe-exchange and harm reduction programs (all with rapid test programs)



Overall Program Outcomes: December 2014 – March 2017

* Hepatitis C education and prevention services provided

Tips - local implementation of Rapid HCV test programs

1. Set clear & measurable programmatic goals
2. Create a registry of hepatitis C patients & track health outcomes
3. Identify appropriate referral sites & providers for your client population
4. Provide active referrals (i.e. make appointments for clients) - do not expect clients to do this independently
5. Use a team-based approach – avoid isolating your hepatitis C testing programs
6. Coordinated mental health, substance use, and hepatitis treatment services can increase hepatitis C treatment uptake, adherence, and cure⁶

⁶ Zhou K, et al. *Interventions to optimize the care continuum for chronic viral hepatitis: a systematic review and meta-analysis. Lancet, 2016.*

Questions?

Contact:

Jessie Schwartz, RN, MPH

jschwartz2@health.nyc.gov

347-396-2627

Hepfree.nyc

3. HCV RNA testing on the GeneXpert

François Lamoury

*Research Officer
Viral Hepatitis and Clinical Research Program
The Kirby Institute, UNSW Sydney*

Xpert[®] HCV Viral Load assay



- ✓ • Automated, self-contained, single use, random access
- ✓ • European CE-IVD, WHO pre-qualified (plasma only)
- ✓ • Single platform for integration (HIV, HPV, TB)
- ✓ • Minimal training, fast (108min)
- ✓ • Multiple configurations



- Not available in all countries
- Cost - pricing per test and platform access.

Method: Plasma versus finger-stick samples

Venous whole blood

Xpert® HCV Viral Load



- 1 Collect venous whole blood by venepuncture



- 2 Centrifuge



- 3 Load 1.2mL plasma into Xpert® HCV Viral load cartridge



- 4 Result in 108min (“fast”)
 - WHO pre-qualified**
 - CE - IVD marked**
 - Not yet available in the US**

Finger-stick capillary blood

Xpert® Fingerstick HCV Viral Load



- 1 Collect 100µL capillary blood by finger-stick into a Minivette



- 2 Load 100µL capillary blood into Xpert® Fingerstick HCV Viral load cartridge



- 3 **Result in 58min (“rapid”)**
 - Research Use only**
 - Not registered**
 - Targeted availability 2018**

Open access resources / videos – available soon...

Examples



SARSTEDT® SAFETY- LANCET SUPER



Order number - 85.1015
 Safety lancet super, violet, blade 1.5 mm, penetration depth 1.6 mm - disposable latest generation penetration aid for collecting capillary blood.

Penetration Depth - 1.6mm
Blade width - 1.5mm

BRIEMARPAK® SKIN CLEANSING SWABS



Order number - 5530 / 200
 Swabs saturated with 70% v/v Isopropyl Alcohol

LAB BENCH COAT



Order number -
 Disposable, spill proof synthetic bench cover fabric

Size - 17-1/2" x 24"

MINIVETTE® POCT 100µL K3E



Order number - 17.2112.101
 Minivette® POCT 100 µL, K3EDTA, violet for Capillary blood collection

Sample Volume - 100 µl

CURITY™ SHEER ADHESIVE BANDAGE



Order number - 44120
 Sheer adhesive bandage spot 2.2 cm

MULTIGATE® STERILE COTTON BALLS



Order number - 02-222P
 Sterile cotton wool balls 5 pack

VER 1.0 AUGUST 2017

LANCET TYPES – PUSH BUTTON ACTIVATED

MiniCollect® safety



Lancet type: Blade and Needle options available
Blade Depth: 1.0mm (pink) / 1.5mm (green) / 2.0mm (blue)
Needle Gauge: 28G penetration depth 1.25mm (lavender)
 23G penetration depth 2.25mm (Orange)

Activation: Push-button activation
Product Ref: 450429
www.gb.com/reenalytics

Haemolancet Plus®



Lancet type: Blade and Needle options available
Blade Depth: 1.2mm(pink) / 1.6mm(purple)
Needle gauge: 18G penetration depth 1.8mm (yellow)
 21G penetration depth 1.8mm (green)
 25G penetration depth 1.4mm (dark blue)
 28G penetration depth 1.6mm (light blue)

Activation: Push: button activation
Product Ref: 7586
www.haemedic.com

SARSTEDT® Safety



Lancet type: Blade and Needle options available
Blade Depth: 1.2mm (Pink) / 1.6mm (Purple)
Blade Width: 1.5mm
Needle gauge: 18G penetration depth 1.8mm (yellow)
 21G penetration depth 1.8mm (Green)
 28G penetration depth 1.6mm (Blue)

Activation: Push: button activation
Product Ref: 85.1019/85.1018/85.1017/85.1016/85.1015
www.sarstedt.com

Accu-Check® Safe-T-Pro



Lancet type: Needle Only, Variable depth adjustment
Blade Depth adjustable: 3 settings
 Low (1.3mm)
 Medium (1.8mm)
 High (2.3mm)

Activation: Push-button activation
Product Ref: <https://www.accu-check.com.au/lancing-devices/safe-t-pro-plus>

Sterilance® Lite 2



Lancet type: Blade and needle options available
Blade depth: 1.8mm (Green)
Needle gauge: 21G penetration depth 2.4mm (Pink)
 21G penetration depth 1.8mm (Orange)
 26G penetration depth 2.4mm (Blue)
 26G penetration depth 1.8mm (Yellow)
 28G penetration depth 1.8mm (Purple)

Activation: Push-button activation
Product Ref: SL01-132818/132618/132118/132124
www.pathtech.com.au

LANCET TYPES – CONTACT ACTIVATED

BD Microtainer® contact activated



Lancet type: Blade and Needle options available
Blade Depth: 1.5mm Blade Width: 2.0mm (Blue)
Needle gauge: 30G penetration depth 1.5mm (purple)
 21G penetration depth 1.8mm (pink)

Activation: contact activated
Product Ref: 366594 (blue)/366593(pink)/366594(blue)
www.bd.com/vacutainer

Medilance® Safety lancets



Lancet type: Blade and Needle options available
Blade Depth: 0.8mm penetration depth: 2.0mm (Yellow)
Needle gauge: 30G penetration depth 1.2mm (light green)
 25G penetration depth 1.5mm (purple)
 21G penetration depth 1.8mm (blue)
 21G penetration depth 2.4mm (Dark green)

Activation: contact activated
Product Ref: 366594 (blue)/366593(pink)/366594(blue)
www.bd.com/vacutainer

Sterilance® press 2



Lancet Type: Blade and needle options available
Blades depths: 1.8mm (light green) / 2.2mm (orange) / 2.8mm (Pink)
Needle gauge: 28G penetration depth 1.8mm (Purple)
 26G penetration depth 1.8mm (Yellow)
 21G penetration depth 1.8mm (blue)
 21G penetration depth 2.2mm (Orange)

Activation: contact activated
Product Ref: SL05062818/062618/062118/062122/062128

Xpert[®] Fingerstick HCV Viral Load assay

(Not available for diagnostic use)

Consumables



Lab Bench coat



SARSTEDT[®] Safety Lancet Super



MULTIGATE[®] sterile Cotton Balls



Curity[™] Sheer Adhesive Bandage



Minivette[®] POCT 100µl K3E




BRIEMARPAK[®] Skin Cleansing Swabs



Examination Gloves

Choice




Fingerstick capillary blood collection and sample loading

1




2



3



4



5



6



7



8



9



10



11



12



*Demonstration of capillary blood by fingerstick
and minivette collection for the GeneXpert*

4. Dried Blood Spot sampling and testing

Tanya Applegate

Senior Lecturer

The Kirby Institute,

UNSW Sydney Australia


Erika Castro

Head of Internal Medicine in Addiction clinic



Centre Hospitalier Universitaire Vaudois

Lausanne, Switzerland

What are Dried blood Spots (DBS)?



Centralized testing



Decentralized services

What are the pros and cons of DBS?



Pros

- ✓ Linkage to care
- ✓ Easy and inexpensive to collect
- ✓ No medical training required
- ✓ Facilitate access
- ✓ Self-collection possible at home
- ✓ Reflex testing (no second test)
- ✓ RNA, Ab (including RDT), core antigen

Cons

- ✗ Low sample volume
- ✗ Reduced sensitivity
- ✗ Analyte degradation can occur
- ✗ Centralised testing in specialized lab
- ✗ Processing, storage
- ✗ Cost (?? country dependent)
- ✗ **No registered tests for clinical use**

How are dried blood spots collected?

Consumables



Bench coat



Safety Lancet



Sterile Cotton Balls



Adhesive Bandage



Alcohol Cleansing Swabs



Gloves



Whatman® 903 protein saver card



Humidity Indicator card



Absorbent packets




Whatman® Foil barrier bags

Fingerstick capillary dried blood spot collection

1



2



3



4




5




6



7



8



9



10



Open access resources / videos – available soon



HCV DRIED BLOOD SPOT (DBS) COLLECTION GUIDE

1 ASSEMBLE DBS CONSUMABLES



Whatman® 903 protein saver card



Whatman® Foil barrier reusable bags



SARSTEDT® Safety-Lancet Super



BRIEMARPAK® Skin Cleansing Swabs



Clariant Humidity Indicator card



MiniPax® absorbent packets



MULTIGATE® sterile Cotton Balls



Curity™ Sheer Adhesive Bandage



Examination Gloves



Lab Bench Coat

2 PATIENT ASSESSMENT AND PREPARATION



Ask patient to warm hands by rubbing together



Increase circulation by doing fist clenches



Massage to further help blood flow




Best practice is to use the middle ring finger of the non-dominant hand




Assess suitable fingers

3 SITE CLEANING AND DISINFECTION



Use 1st swab Clean the finger well moving in both directions



Use 2nd swab to disinfect in a single stroke

4 PERFORMING FINGERSTICK AND DBS COLLECTION

Do not touch the spots with bare fingers to avoid contamination



Open pre-labelled protein saver card. Do not touch the spots with bare fingers to avoid contamination



Show and explain to the patient that the lancet is unused then break seal




Hold lancet firmly against finger on the side closest to the little finger and press the button.



Apply gentle pressure and allow a drop of blood to form and fall onto the card. Continue until five spots are collected. DO NOT DAB FINGER ONTO THE CARD.



Position the hand flat on the surface



Determine the best site for taking the sample which is either side of the midline of the finger




Wipe away the first blood drop



Stop blood flow by applying pressure for 5 minutes and place spot band on finger

5 DRYING AND PACKING OF DBS FOR TRANSPORT



Dry cards horizontally in a DBS drying rack for minimum 4 hrs or overnight



Close flap on DBS card insert into a sealable foil bag then add humidity indicator card + two absorbent packs. Apply pressure to ensure air is expelled from foil bag prior to sealing

6 STORAGE OF DBS CARDS



Sealed foil bags can be stored at room temperature away from sunlight and moisture in a cool, dry environment for up to 14 days before sending in standard postal envelope to a central reference laboratory

References:






1. World Health Organization, Blood collection and Handling – Dried Blood Spots (DBS). | http://cdrwww.who.int/diagnostics_laboratory/documents/guidance/pm_module14.pdf
2. WHO manual for HIV drug resistance testing using dried blood spot specimens march 2010 (updated July 2012). http://apps.who.int/iris/bitstream/10665/75829/1/WHO_HIV_2012_30_eng.pdf?ua=1

What makes a good DBS?

Scoring DBS – valid / invalid

Quantity










DBS quantity encompasses both the number of DBS collected (i.e., number of DBS collected out of maximum of 5) and the amount of blood collected on the filter paper (i.e., whether the area was fully covered with blood, half, spotted etc.). This information must be recorded on the DBS receipt log and if necessary must be described on the 'DBS quantity comment' section.

DBS Quantity	Image	Comment
		Sufficient
		Insufficient
		Insufficient
	<p>Front view</p>  <p>Back view</p> 	Not soaked through

Quality


DBS quality

DBS quality determines whether a DBS specimen is valid or invalid. The laboratory receiving the DBS specimen must classify whether a sample is considered valid or invalid. In the case that a specimen is classified as invalid, it is important that the reason for such classification is indicated. Please refer to the images below when recording the DBS specimen quality score. Use the scoring code indicated in this guide in filling out the DBS receipt log.

DBS Quality score	Image	Comment
1		Insufficient quantity for testing
2		Specimen is scratched or abraded
3		Specimen was not dry before mailing
4		Specimen is supersaturated
5		Specimen appears diluted, discoloured or contaminated
6		Specimen exhibit serum separating from cells may also appear as serum rings
7		Specimen appears to be clotted or layered
8		Specimen obtained with incorrect filter paper
9		No blood spot was added

Tips to improve DBS collection

- The best place middle or 4th finger
 - Non-dominant hand
- Prick the finger on the side (not on the pad).
 - Nearest the little finger (to help the next steps)
- Let the blood accumulate until a drop forms.
 - You can encourage blood flow
 - “To milk or not to milk?”
- Let the blood drop where possible



DBS collection demonstration

How are DBS stored and tested?

Storage

1

**Intact card
(Research)**



Foil bag



Drawers



-70 freezer

2

**Punch / elute
(Service provider)**



Eluate stored



Racks

Testing

1

Punch



Elute



2



HCV RNA assays (research use only)

1



**Panther system
(Hologic)**

2



**m2000sp/rt
(Abbott)**

3



**AmpliPrep / COBAS
Taqman (Roche)**


HCV RNA quantification on DBS

A concept of proof in Swiss settings

Disclosure

This study was co-sponsored with an unrestricted grant of Gilead.

HCV RNA quantification on DBS – A Swiss study



A Swiss case study – why?

Why HCV screening with DBS in tertiary referral hospital?



A Swiss case study - background

The need of optional blood collection strategies for people who inject drugs with difficult venous


- Poor vascular health consecutive to years of intravenous drug injection is a common constraint.
 - Routine limb vein puncture can become a barrier for screening and treatment of HCV infection.
-

Hepatitis C Virus RNA quantitation using DBS

Erika Castro, Rachel Mamin, Cyril Andre, Lorenza Oprandi

P12
INHSU
2016

**CORRELATION OF PATIENT'S HCV VIREMIA ACCORDING TO BLOOD DRAW STRATEGY:
DBS vs PLASMA/EDTA**
n = 16




HCV RNA quantification:

COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test v2.0).

Conclusions

- We found a positive and strong correlation of patient's DBS and plasma/EDTA HCV viremia values.
- In this dataset EDTA plasma RNA average was 5.16 log (range: 1.17 6.85) with a limit detection value of 1.17 log (≤ 15 IU/mL).
- DBS RNA detection limit was 2.69 log (480 IU/mL).




HCV RNA quantification on DBS:

A proof of concept in Swiss settings

Small dataset..to argue for quantitative use.


HCV RNA quantification on DBS:

A proof of concept in Swiss settings



HCV RNA quantification on DBS:

A proof of concept in Swiss settings



1. CHUV: DBS central lab + Addiction medicine clinic
2. Unité de traitement des addictions, Dr Laurianne Mer.
3. Fondazione Epatocentro Ticino, Dr Alberto Moriggia.

Poster 24

A Cost-Effectiveness Analysis of Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing

François Girardin¹, Natalie Hearmon², Francesco Negro³, Lucy Eddowes², Philip Bruggmann⁴, Erika Castro^{5*}

¹Medical Direction and Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals (HUG), University of Geneva, Geneva, Switzerland; ²Costello Medical Consulting Ltd, Cambridge, UK; ³Divisions of Gastroenterology and Hepatology, and of Clinical Pathology, HUG, Geneva, Switzerland; ⁴ARUD, Centres for Addiction Medicine, Zurich, Switzerland; ⁵Center for Addiction Medicine, Service of Community Psychiatry, Department of Psychiatry, University of Lausanne (CHUV), Lausanne, Switzerland; *Erika.Castro-Bataenjer@chuv.ch.

- Cost-effective due to the increased screening uptake via rapid saliva and DBS testing instead of venipuncture.
 - The proposed test package is less expensive than venipuncture.
 - Would likely increase the number of diagnoses and result in a greater number of PWID initiating treatment.
-

6. Closing remarks

Point of care testing strategies can globally:

- **Scale-up HCV screening/monitoring in LMIC and HIC**
 - **Improve linkage to care**
 - **Be adapted to settings' needs**
 - **Enhance collaborative partnerships**
-

7. Acknowledgments

Study participants, coordinators, nurses, investigators

Erica Castro

Teri Roberts

Lorenza Oprandi

Jessie Schwartz

Emmanuel Fajardo

Rachel Mamin

Francois Lamoury

Jenny Iversen

Cyril Andre

Jordan Feld

Lisa Maher

Philip Cunningham

Jilian Sacks

Gail Matthews

Beth Catlett

Jason Grebely

Marianne Martinello

Charles Crew

Greg Dore

Yasmin Mowat

Celia Aitken

Danica Martinez

Amanda Erratt

Rory Gunston

Brendan Jacka

Jasmine Skurowski

John Dillon

Sofia Bartlett

Sophie Quiene

Georgina McAllister

Indika Jayasinghe

Sahar Bajis

Samantha Shepherd

Michelle Holder

Alison Marshall

Sharon Hutchinson

Pip Marks

Evan Cunningham

Orasure for providing training today

Thanks in advance.....Abbott, Hologic and Roche for pushing DBS registration!

Orasure demonstration – for those who are keen.
